Press Releases

Continues to Strengthen and Broaden Intellectual Property Portfolio   BOSTON, MA – September 9, 2015 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”) a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, announced today that the United States Patent & Trademark Office has allowed claims for its United States… Read More

BOSTON, MA – September 1, 2015 – InspireMD, Inc. (NYSE MKT: NSPR) a leader in stent embolic prevention systems (“EPS”) and thrombus management technologies, today announced that its Chief Executive Officer, Alan Milinazzo, will present at the Rodman & Renshaw 17th Annual Global Conference on Thursday, September 10, 2015 at 10:25 a.m. ET. The conference… Read More

BOSTON, MA – August 5, 2015 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in stent embolic prevention systems (“EPS”), today announced its financial and operating results for the second quarter ended June 30, 2015. The Company is in the second full quarter of a strategic transition into penetrating the carotid… Read More

Accelerates InspireMD’s Access into Key Geographic & Specialty Markets Enables CGuardTM to be Commercialized as Part of a Total Systems Solution BOSTON, MA – August 5, 2015 – InspireMD, Inc. (NYSE MKT: NSPR) a leader in stent embolic prevention systems (“EPS”) and thrombus management technologies, today announced that it has entered into a partnership with… Read More

BOSTON, MA – July 14, 2015 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection systems, announced today that it will release its full financial results for the second quarter ended June 30, 2015 on Wednesday, August 5th after the market close, followed by a conference call at 4:30… Read More

Recognized for Successful Introduction of New and Innovative Products, with Emphasis on Quality and Customer Value BOSTON, MA – July 7, 2015 — InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection systems (“EPS”), a leader in embolic protection systems (“EPS”), today announced that its MGuard Prime™ Embolic Protection System integrated… Read More

PARADIGM Evaluation Reports CGuard™ Favorable Outcomes in All-Comer Carotid Disease Population BOSTON, MA – May 12, 2015 — InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection systems (“EPS”), today announced that its CGuard™ Embolic Prevention System reported positive results in PARADIGM, lead by principle investigator Prof. Piotr Musialek, at… Read More

Clinical Presentations Highlight Carotid and Coronary Applications of InspireMD’s Proprietary MicroNet™ Technology BOSTON, MA – May 12, 2015 — InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection systems (“EPS”), today announced that there will be multiple clinical presentations across a broad range of indications for MicroNet™ Technology at the… Read More

BOSTON, MA – May 11, 2015 — InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection systems (“EPS”), today announced its financial and operating results for the first quarter ended March 31, 2015. Alan Milinazzo, CEO of InspireMD, commented, “The first quarter marked the beginning of our full shift in… Read More

BOSTON, MA – April 27, 2015 — InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), today announced it received approval to commercialize MGuard™ Prime™ with MicroNet™ technology in Brazil. The approval was granted by the Agência Nacional de Vigilância Sanitária (ANVISA). The BRICCS (Brazil, Russia, India, China, South Africa and South Korea) coronary stents… Read More